TOP > 外国特許検索 > CELL SHEET FOR VITAL TRANSPLANTATION AND METHOD FOR PRODUCING SAME

CELL SHEET FOR VITAL TRANSPLANTATION AND METHOD FOR PRODUCING SAME NEW

外国特許コード F200010008
整理番号 (17004-JP01)
掲載日 2020年1月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP017594
国際公開番号 WO 2019208688
国際出願日 平成31年4月25日(2019.4.25)
国際公開日 令和元年10月31日(2019.10.31)
優先権データ
  • 特願2018-084565 (2018.4.25) JP
発明の名称 (英語) CELL SHEET FOR VITAL TRANSPLANTATION AND METHOD FOR PRODUCING SAME NEW
発明の概要(英語) The present invention pertains to a cell sheet for vital transplantation, said cell sheet being provided with mesenchymal stem cells on a surface at an average cell density of 3.0×104 cells/cm2 or less. The present invention also pertains to a method for producing a cell sheet for vital transplantation, said method comprising a step for inoculating mesenchymal stem cells in a cell culture support having a three-dimensional structure formed of a fiber at a ratio of 3.0×105 cells/cm2 or less and a step for culturing the mesenchymal stem cells to thereby prepare a cell sheet having an average cell density of 3.0×104 cells/cm2 or less.
従来技術、競合技術の概要(英語) BACKGROUND ART
Mesenchymal stem cells (Mesenchymal stem cell, hereinafter also referred to as MSC) is, perhaps the ability to self-replicating and have the ability to a stem cell, osteoblast, chondrocyte cells, fat cells, muscle cells to differentiate into cells such as mesenchymal belonging to the well, such as hepatocytes or cells also have the ability to differentiate than definitive. In the MSC, itself produced by the liquid agent and cell adhesion interactions paracrine effect have been known. MSC is, based on these actions, the repair of the target tissue or cell, a regenerative capacity, and exhibits an anti-inflammatory such as ability to control, as a result, various diseases are considered to represent the therapeutic effect.
The MSC, can be easily isolated and cultured up the force in the growth, the number of cells in a short time can be secured to the implantable, immune rejection can be autografts can not, be less ethical issues, it is not necessary to pre-treatment by low immunogenicity allograft practical reasons, as the material of the ideal cell transplantation therapy, a treatment for various diseases has been applied to study.
MSC of the cell transplantation therapy of disease expected to be applied to one of the renal disease, particularly chronic kidney disease. Chronic kidney disease are, renal disorders represented by proteinuria, and glomerular filtration rate as an indicator of renal function either or both of the state has persisted for more than six months refers to 3, 8 adult person in Japan and affecting 1. Chronic kidney disease symptoms and progress to end stage renal disease, drug treatment effect cannot be expected, an increase in the artificial dialysis in many patients. Artificial dialysis be symptomatic, chronic renal failure patients due to a need to continue to receive an artificial dialysis over the lifetime, the physical and economic burden to a patient is large. Further increase in dialysis medical costs, medical economy, a concern has been a problem.
The inventors of the present invention, the MSC is used to establish cell transplantation therapy in the course of, for example a diabetic patient in the patient's abnormal MSC in the MSC, specifically as described above or a variety of capability of the capability of the MSC and compared with that of a normal as a result, the effect of disease or therapeutic effect is lost as compared with the normal MSC MSC is reduced, and mammals extract from the associated MSC and activating the abnormal treatment efficacy can be restored, and such activation treatment using autografts the MSC can be found and the like, attached to mammals as an active ingredient extract from abnormal activation agent for the MSC to the invention, and filed a patent application (Patent Document 1). The activation agent is, in particular, the treatment step becomes necessary for the patient at a point of the MSC can be autografts, has important significance.
On the other hand, in the cell transplantation therapy, used to reduce the amount of the MSC, centralized MSC sites required to be capable of formulation of the topical application is being examined. Of the cell transplantation therapy to renal disease as the MSC, the MSC of the sheet composition is applied to the kidney cell can approach is to treat kidney disease have been reported (Patent Document 2). The cells of the sheet composition is a stimuli-sensitive media on the substrate and seeded culture MSC, to separate the cells stimulated by peeling are prepared.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAPPORO MEDICAL UNIVERSITY
  • 発明者(英語)
  • CHIKENJI Takako
  • FUJIMIYA Mineko
  • SAITO Yuki
  • NAKANO Masako
  • KONARI Naoto
  • OTANI Miho
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close